Literature DB >> 20202864

Reversal of impaired myocardial beta-adrenergic receptor signaling by continuous-flow left ventricular assist device support.

Shahab A Akhter1, Karen M D'Souza, Ricky Malhotra, Michelle L Staron, Tracy B Valeroso, Savitri E Fedson, Allen S Anderson, Jai Raman, Valluvan Jeevanandam.   

Abstract

BACKGROUND: Myocardial beta-adrenergic receptor (beta-AR) signaling is severely impaired in chronic heart failure (HF). This study was conducted to determine if left ventricular (LV) beta-AR signaling could be restored after continuous-flow LV assist device (LVAD) support.
METHODS: Twelve patients received LVADs as a bridge to transplant. Paired LV biopsy specimens were obtained at the time of LVAD implant (HF group) and transplant (LVAD group). The mean duration of LVAD support was 152 +/- 34 days. Myocardial beta-AR signaling was assessed by measuring adenylyl cyclase (AC) activity, total beta-AR density (B(max)), and G protein-coupled receptor kinase-2 (GRK2) expression and activity. LV specimens from 8 non-failing hearts (NF) were used as controls.
RESULTS: Basal and isoproterenol-stimulated AC activity was significantly lower in HF vs NF, indicative of beta-AR uncoupling. Continuous-flow LVAD support restored basal and isoproterenol-stimulated AC activity to levels similar to NF. B(max) was decreased in HF vs NF and increased to nearly normal in the LVAD group. GRK2 expression was increased 2.6-fold in HF vs NF and was similar to NF after LVAD support. GRK2 activity was 3.2-fold greater in HF vs NF and decreased to NF levels in the LVAD group.
CONCLUSIONS: Myocardial beta-AR signaling can be restored to nearly normal after continuous-flow LVAD support. This is similar to previous data for volume-displacement pulsatile LVADs. Decreased GRK2 activity is an important mechanism and indicates that normalization of the neurohormonal milieu associated with HF is similar between continuous-flow and pulsatile LVADs. This may have important implications for myocardial recovery. Copyright 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202864      PMCID: PMC2876229          DOI: 10.1016/j.healun.2010.01.010

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  27 in total

1.  Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer.

Authors:  S A Akhter; C A Skaer; A P Kypson; P H McDonald; K C Peppel; D D Glower; R J Lefkowitz; W J Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 2.  Structure and mechanism of the G protein-coupled receptor kinases.

Authors:  J Inglese; N J Freedman; W J Koch; R J Lefkowitz
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

3.  In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function.

Authors:  S A Akhter; A D Eckhart; H A Rockman; K Shotwell; R J Lefkowitz; W J Koch
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices.

Authors:  Vinay Thohan; Sonny J Stetson; Sherif F Nagueh; Carlos Rivas-Gotz; Michael M Koerner; Javier A Lafuente; Matthias Loebe; George P Noon; Guillermo Torre-Amione
Journal:  J Heart Lung Transplant       Date:  2005-05       Impact factor: 10.247

5.  Ex vivo adenovirus-mediated gene transfer to the adult rat heart.

Authors:  A P Kypson; K Peppel; S A Akhter; R E Lilly; D D Glower; R J Lefkowitz; W J Koch
Journal:  J Thorac Cardiovasc Surg       Date:  1998-03       Impact factor: 5.209

6.  Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart.

Authors:  M Ungerer; G Parruti; M Böhm; M Puzicha; A DeBlasi; E Erdmann; M J Lohse
Journal:  Circ Res       Date:  1994-02       Impact factor: 17.367

7.  Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice.

Authors:  H A Rockman; K R Chien; D J Choi; G Iaccarino; J J Hunter; J Ross; R J Lefkowitz; W J Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

8.  Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor.

Authors:  W J Koch; H A Rockman; P Samama; R A Hamilton; R A Bond; C A Milano; R J Lefkowitz
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

9.  Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure.

Authors:  K B James; P M McCarthy; J D Thomas; R Vargo; R E Hobbs; S Sapp; E Bravo
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

10.  Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase.

Authors:  N J Freedman; S B Liggett; D E Drachman; G Pei; M G Caron; R J Lefkowitz
Journal:  J Biol Chem       Date:  1995-07-28       Impact factor: 5.157

View more
  9 in total

Review 1.  betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease.

Authors:  Henriette Brinks; Walter J Koch
Journal:  J Cardiovasc Transl Res       Date:  2010-07-10       Impact factor: 4.132

Review 2.  G protein coupled receptor kinases as therapeutic targets in cardiovascular disease.

Authors:  Stephen L Belmonte; Burns C Blaxall
Journal:  Circ Res       Date:  2011-07-22       Impact factor: 17.367

3.  Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device.

Authors:  Deepak K Gupta; Hicham Skali; Jose Rivero; Patricia Campbell; Leslie Griffin; Colleen Smith; Courtney Foster; Brian Claggett; Robert J Glynn; Gregory Couper; Michael M Givertz; Mandeep R Mehra; Marcelo Di Carli; Scott D Solomon; Marc A Pfeffer
Journal:  J Heart Lung Transplant       Date:  2014-01-27       Impact factor: 10.247

Review 4.  Reverse Remodeling With Left Ventricular Assist Devices.

Authors:  Daniel Burkhoff; Veli K Topkara; Gabriel Sayer; Nir Uriel
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 23.213

5.  Myocardial recovery evaluation from ventricular assist device in patients with dilated cardiomyopathy.

Authors:  Takayuki Gyoten; Eisuke Amiya; Osamu Kinoshita; Masaki Tsuji; Mitsutoshi Kimura; Masaru Hatano; Minoru Ono
Journal:  ESC Heart Fail       Date:  2022-05-10

Review 6.  Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy.

Authors:  Tomas Hnat; Josef Veselka; Jakub Honek
Journal:  ESC Heart Fail       Date:  2022-04-18

7.  Myocardial recovery during mechanical circulatory support: cellular, molecular, genomic and organ levels.

Authors:  Michael Dandel; Roland Hetzer
Journal:  Heart Lung Vessel       Date:  2015

Review 8.  G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism.

Authors:  Meryl C Woodall; Michele Ciccarelli; Benjamin P Woodall; Walter J Koch
Journal:  Circ Res       Date:  2014-05-09       Impact factor: 17.367

Review 9.  Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes.

Authors:  Gabriele Giacomo Schiattarella; Fabio Magliulo; Fabio Cattaneo; Giuseppe Gargiulo; Anna Sannino; Anna Franzone; Marco Oliveti; Cinzia Perrino; Bruno Trimarco; Giovanni Esposito
Journal:  Front Cardiovasc Med       Date:  2015-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.